Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Klinic

Eve
Graded #210

Higher grade

vs+5.200000000000003
Klinic
Graded #313

Lower grade

The verdict

Eve takes it — 66/100 to 60.8/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +9
54
45
Dose & formulationEve +35
88
53
Clinical oversightEven
79
79
Labs & monitoringKlinic +12
52
64
FulfillmentKlinic +9
67
76
Contract termsKlinic +14
41
55
Eve · left barKlinic · right bar

The numbers

MetricEveKlinic
WeighScore66/10060.8/100
GradeCC
Scorecard rank#210#313
Semaglutide$195/mo (compounded)Not disclosed
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
Eve

Graded #210 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
Klinic

Graded #313 · C

Strengths

  • LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
  • Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
  • Klinic handles all prior authorization—patient never manages PA paperwork
  • Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
  • Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder

Where it loses points

  • Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
  • No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
  • Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
  • No labs or dedicated nutrition/coaching program included in any plan
  • Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard